Printer Friendly

Glaxo to market bird-flu vaccine.

BRITISH pharmaceutical giant GlaxoSmithKline said yesterday it had received permission from European medical regulators to market the human bird flu vaccine it has already sold to several governments in preparation for a pandemic.

The ruling from the European Medicines Agency makes Prepandrix, which targets the H5N1 virus, the first vaccine to receive a licence for pre-pandemic use in all 27-member European Union states.

Glaxo, which has already spent pounds 1bn developing the vaccine, has orders from Switzerland and the US based on the bird flu virus from Vietnam.

Switzerland has ordered 8m doses - enough to cover the country's entire population. The US Department of Health and Human Services has ordered 27.5m doses.

Experts believe H5N1 is the most likely candidate to mutate into a pandemic virus.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Daily Post (Liverpool, England)
Date:May 20, 2008
Previous Article:Council stalemate dragging on; Meeting fails to end deadlock.
Next Article:Liverpool surgeon in chimp operation first.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |